Also, the frequency rate of patients with high levels of ALT and AST was significantly decreased in the metformin regimen, which confirms the presumption of the potential role of such medication in the stabilization of liver biochemistry or even the enhancement of liver biochemistry in the NAFLD patients [13]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.